 ?您的位置：對照品 > 試劑耗材 > 生化試劑 > |
|
|
|
| 產(chǎn)品基本信息 |
|
| 產(chǎn)品編號：122335 |
| 產(chǎn)品名稱：柔紅霉素 鹽酸鹽, ≥90% (HPLC) |
| 產(chǎn)品CAS：23541-50-6 |
| 規(guī)格含量：5mg |
| 產(chǎn)品價格：2000 |
| 聯(lián)系我們: |
 |
|
 |
|
|
| 產(chǎn)品詳細(xì)介紹 |
柔紅霉素 鹽酸鹽, ≥90% (HPLC)
Product Name： Daunorubicin hydrochloride
別名:道諾霉素 鹽酸鹽
CAS號:23541-50-6
分子式:C27H29NO10 · HCl
分子量:563.98
貯存： 儲存溫度2-8°C
生化和生理學(xué)機理：
IC50 value： 0.02uM (Ki for inhibition of DNA synthesis) Daunomycin is an important anti-tumor agent, mainly used in the treatment of acute leukemias. Daunomycin can inhibit DNA synthesis by the way of binding to DNA(intercalation), causing an increase in the melting temperature of the DNA. in vitro： At Daunorubicin concentrations exceeding approximately 2-4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells [1]. Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase[2]. Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells[3]. in vivo： daunorubicin inhibited the proliferation of KG1a cells in a dose and time dependent manner (r = 0.983, P < 0.01).Daunorubicin could reduce the mRNA and protein levels of Eps8 expression in dose and time dependent manners in KG1a cells (r = 0.979, P < 0.05) [4]. Clinical trial： N/A
|
|
|
|
|
